Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •1. Pregnancy, defined as a positive result of a highly sensitive urine or serum pregnancy test, or lactation
• •2. Clinical diagnosis of systemic lupus erythematosus (SLE)
• •3. History of any hypersensitivity to riliprubart or any of its components, or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody
• •4. Any country-related specific regulation that would prevent the participant from entering the study
• •5. Accommodation in an institution because of regulatory or legal order; for instance, a prisoner or participant who is legally institutionalized
• •6. Unsuitability for participation as judged by the Investigator, whatever the reason, including: medical or clinical condition, potential risk of participant noncompliance with study procedures, or any other clinically significant change in the participants' medical condition
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.